Edwards Lifesciences has lifted its full-year 2026 growth outlook to between 9% and 11%, up from 8% to 10% previously, due to ‘better than expected’ performance in Q1.
The medtech giant reported revenues of around $1.65bn in Q1, driven by steady double-digit growth across its portfolio. With the percentage uplift for the full year, Edwards now anticipates sales of $6.5bn to $6.9bn, with earnings mooted to fall in the $2.95 to $3.05 per share range, up from $2.90 to $3.05 previously.
Edwards released its Q1 results after the market closed on 23 April. The company’s shares on the New York Stock Exchange (NYSE), correct as at 12pm BST on 24 April, were up by over 2% at $81.51, versus $79.72 at market close on the prior day.
Edwards transcatheter aortic valve replacement (TAVR) business pulled in the majority of the quarter’s sales at around $1.2bn, representing a year-over-year (YoY) growth rate of 14.4%.
GlobalData analysis reveals that the TAVR market is projected to reach a valuation of $14.9bn in 2034, up from $6.8bn in 2024. Further data from GlobalData indicates that Edwards currently holds $4.53bn in revenue in the TAVR space, with a US market share of over 60%.
Elsewhere across the business, Edwards reported 10.1% growth in its surgical portfolio to $276.2m. Meanwhile, although Edwards’ transcatheter mitral and tricuspid therapies segment was the smallest revenue driver, pulling in $175.1m, it saw the most significant growth at 59.9% YoY.
Bernard Zovighian, Edwards’ CEO, commented: “Building on a year in 2025 marked by solid financial performance and strategic progress, we delivered another strong quarter in Q1, achieving 12.7% sales growth, which reflects the impact and durability of our focused strategy. We remain dedicated to solving large, urgent and complex patient needs and pursuing unique opportunities to innovate and lead in structural heart disease.”
Medtech rival Boston Scientific also released its Q1 financials this week. While the company reported steady Q1 performance, unlike Edwards, it chose to temper its prior full-year growth outlook, citing “ongoing competitive dynamics”.
“Edwards Lifesciences raises FY26 guidance following strong Q1” was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
